60 completed, 25 terminated, 21 unknown, 10 withdrawn. 80 Phase 2, 41 Phase 1, 13 Phase 3, 4 Not applicable, 4 Phase 4.
Follow Arsenic Trioxide: new trials by email Literature Review of Arsenic Trioxide trials Research Report on Arsenic Trioxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin - Medulloblastoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 78 | 2026-10-01 | 2026-10-02 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-30 |
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. ATRA, Arsenic Trioxide (ATO), Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Daniel Breadner | 10 | 2026-02-15 | 2026-01-16 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) Arsenic Trioxide (ATO) - Low-risk Myelodysplastic Syndromes | Phase 1 | Recruiting | Groupe Francophone des Myelodysplasies | 24 | 2025-07-22 | 2026-09-10 |
| Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia Venetoclax, All-trans retinoic acid, Arsenic Trioxide (ATO) - Acute Promyelocytic Leukemia (APL) | Not applicable | Active not recruiting | Anhui Medical University | 28 | 2025-07-01 | 2025-09-23 |
| Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma Arsenic trioxide, MAPK inhibitors, Chemotherapy - Neuroblastoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 92 | 2025-05-01 | 2025-04-18 |
| Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state - Acute Promyelocytic Leukemia (APL) | Phase 1 | Completed | SDK Therapeutics, Inc. | 12 | 2025-03-11 | 2025-11-18 |
| Oral-ATO for TP53-mutated Myeloid Malignancies Oral arsenic trioxide - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Recruiting | The University of Hong Kong | 30 | 2025-02-07 | 2025-06-10 |
| Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL interferon α-2b - Tumour | Not applicable | Unknown | Zhejiang Provincial People's Hospital | 15 | 2024-05-01 | 2024-06-10 |
| Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer Arsenic trioxide - Pediatric Cancer, Li-Fraumeni Syndrome | Phase 2 | Recruiting | Yang Li | 50 | 2023-12-13 | 2024-01-03 |
| Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection Sodium arsenite chloride injection - Adverse Reaction, Cardiotoxicity | Unknown | Qianfoshan Hospital | 400 | 2023-01-29 | 2023-09-29 | |
| Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL Arsenic trioxide, all-trans retinoic acid - Promyelocytic Leukemia | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2022-07-01 | 2022-10-26 |
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia SY-2101, Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 1 | Suspended | Syros Pharmaceuticals | 16 | 2021-09-17 | 2024-01-23 |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation Arsenic trioxide - Refractory Solid Tumors | Phase 2 | Unknown | Ruijin Hospital | 20 | 2021-04-20 | 2021-05-13 |
| Arsenic Trioxide for Structural p53 Mutations Arsenic Trioxide - Arsenic Trioxide, p53 Mutations | Phase 2 | Unknown | Shanghai Changzheng Hospital | 30 | 2021-01-01 | 2021-01-06 |
| Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer Arsenic Trioxide, Itraconazole, Laboratory Biomarker Analysis - Skin Basal Cell Carcinoma | Early Phase 1 | Withdrawn | Jean Yuh Tang | 2020-12-01 | 2020-10-22 | |
| Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation Arsenic trioxide for injection - Ovarian Cancer, Endometrial Cancer | Not applicable | Unknown | Ruijin Hospital | 20 | 2020-06-28 | 2020-07-28 |
| Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia Arsenic Trioxide - Acute Promyelocytic Leukemia | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 100 | 2020-04-14 | 2022-01-04 |
Showing 20 of 132. Sign in to see all of them.
Leukemia (31) · Leukemia, Promyelocytic, Acute (27) · Myelodysplastic Syndromes (18) · Leukemia, Myeloid, Acute (17) · Multiple Myeloma (17) · Neoplasms, Plasma Cell (12) · Leukemia, Myelomonocytic, Chronic (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Anemia, Refractory, with Excess of Blasts (7) · Blast Crisis (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Monocytic, Acute (6) · Lymphoma (6) · Burkitt Lymphoma (5) · Leukemia, Erythroblastic, Acute (5)
Memorial Sloan Kettering Cancer Center (11) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (6) · Northwestern University (4) · CTI BioPharma (3) · Ruijin Hospital (3) · Stanford University (3) · The University of Texas Medical Branch, Galveston (3) · University of Miami (3) · Washington University School of Medicine (3) · Children's Oncology Group (2) · Duke University (2) · First Affiliated Hospital Xi'an Jiaotong University (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Li Junmin (2)
United States (86) · China (21) · Canada (6) · France (6) · Italy (5) · Germany (4) · Spain (4) · Hong Kong (3) · Puerto Rico (3) · Australia (2) · Netherlands (2) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1)
Dan Douer, MD (2) · Deborah A. Thomas, MD (2) · Dennie V. Jones, MD (2) · Huaiyu Wang, Dr. (2) · John D. Hainsworth, MD (2) · Joseph G. Jurcic, MD (2) · Lu Min (2) · Martin S. Tallman, MD (2) · Mikkael A. Sekeres, MD, MS (2) · Muzaffar H. Qazilbash, MD (2) · Scott C. Stromatt, MD (2) · Steven Soignet, MD (2) · Yang Li, Professor (2) · Zhang Sujiang (2) · Alan K. Burnett, MD, FRCP (1)
PMID 35417717, PMID 23841729, PMID 11704843, PMID 12473574, PMID 16651647, PMID 16688776, PMID 16870552, PMID 17182091, PMID 17251932, PMID 17251933, PMID 17959855, PMID 18082257, PMID 20705755, PMID 21815182, PMID 23636398, PMID 24127444, PMID 25245446, PMID 25470713, PMID 25528350, PMID 26440706, PMID 26556035, PMID 26748848, PMID 27142472, PMID 27400939, PMID 27998224, PMID 28003274, PMID 28481359, PMID 28637689, PMID 30026341, PMID 31898521, PMID 32330241, PMID 33495363, PMID 33658052, PMID 34762093, PMID 35760920, PMID 35830931, PMID 39506905, PMID 39584789, PMID 39781038, PMID 40020161, PMID 40453133, PMID 40825164
2025 (2), P30CA006973 (2), P30CA008748 (2), U10CA031946 (2), 2017 (1), K23CA164015 (1), N01CM17003 (1), P30CA016056 (1), P30CA022453 (1), P30CA033572 (1), P30CA043703 (1), P30CA069533 (1), R01CA085748 (1), U01CA062475 (1), U01CA062505 (1)